ClinicalTrials.gg
RecruitingNCT07134777MOVROSUpdated Aug 26, 2026

Mechanisms of Visual Restoration After Occipital Stroke

An observational study in Cortical Blindness, Stroke Ischemic and Vision Loss Partial, sponsored by University of Rochester. Recruiting at 1 site in United States. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by University of Rochester · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
21 Years to 80 Years
Sex
All
01

Study summary

This project will collect brain imaging data to quantify the effects of early visual cortex damage and visual training interventions on the structure and function of the residual visual system. Our goal is to improve understanding of the consequences of permanent visual cortex damage in humans, and to understand how visual training impacts the function of the residual visual system to restore perception.

02

Conditions studied

  • Cortical Blindness
  • Stroke Ischemic
  • Vision Loss Partial
  • Visual Fields Hemianopsia
  • Hemianopia
  • Hemianopia Homonymous
  • Occipital Lobe Infarct

Keywords

  • occipital stroke
  • vision loss
  • Homonymous quadranopsia
03

In context

Ischemic Stroke

2,612 studies on the registry are indexed under Ischemic Stroke; 971 are open to participants now.

This study's planned enrollment of 100 is below the median of 300 across 771 observational studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Cortically blind patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Cortically Blind Subjects (n=50)

Inclusion criteria

Inclusion:

  • Subjects between 21 and 80 years of age
  • Subjects must be residents of the United States or Canada
  • Subjects must exhibit unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range of 21 - 80 years (verified by MRI and/or CT scans)
  • Subjects with reliable visual field defects in both eyes (homonymous defects) as measured by Humphrey, MAIA, Goldmann, and/or equivalent perimetry. This deficit must be large enough to enclose a 5-deg diameter visual stimulus.
  • Subjects must be able to fixate on visual targets reliably for 1000ms, with jitter over less than 1-deg of visual angle.

    o Note: This will be initially assessed by review of visual field reports as supplied by subjects during the screening process. However, we will be unable to fully assess their fixation ability until they start the psychophysics testing in our lab. If at that time we discover that they are unable to maintain adequate fixation, they will be withdrawn from the study.

  • Subjects must be willing, able, and competent to provide their own
  • Subjects must have their own home computer (desktop or laptop) and reliable internet access
  • All subjects must have normal cognitive abilities and memory, sufficient to be able to understand and follow written and oral instructions in English, as well as to remember how to complete visual training at home, on their own, as instructed, for several months.
  • Justification: We can only accept English-speaking subjects due to a lack of resources for supporting those who would require interpreter services. As all of our subjects are required to spend 3-5 days in lab with rigorous testing and training requirements, we must be able to communicate clearly and with minimal misunderstandings. This would require for up to 5-full days of in person interpreter services, for which we do not have funding. Additionally, ongoing communications take place by phone, email, and/or text as a part of home training (for routine check-ins and technical support for example) in the intervals between laboratory visits. This would require us to essentially have "on demand" access to interpreter services, which is simply not feasible.
  • Subjects must be safe and willing to undergo magnetic resonance imaging (MRI) scans

Exclusion criteria

Exclusion:

  • Subjects who have past or present ocular disease interfering with visual acuity
  • Subjects with best-corrected visual acuity (BCVA) worse than 20/40 in either eye
  • Subjects who have documented or suspected damage to the dorsal Lateral Geniculate Nucleus
  • Subjects who have diffuse whole-brain degenerative processes
  • Subjects who have experienced traumatic brain injury
  • Subjects who have any other brain damage deemed by study staff to potentially interfere with training ability or outcome measures
  • Subjects who have oculomotor defects deemed by study staff to potentially interfere with training ability or outcome measures (i.e., by impairing stable fixation during testing or training)
  • Subjects who have documented history of drug/alcohol abuse
  • Subjects who are currently taking neuroactive medications which would impact training, as determined by PI
  • Subjects who have cognitive, memory or seizure disorders
  • Subjects with one-sided attentional neglect
  • Subjects who lack the competence or are otherwise unable to perform the visual training exercises as directed.
  • Subjects who have contradictions to MRI scanning will be excluded. These include: a) central nervous system aneurysm clips; b) implanted neural stimulator; c) implanted cardiac pacemaker or defibrillator; d) cochlear implant; e) ocular foreign body (e.g., metal shavings); f) insulin pump; g) metal shrapnel or bullet; h) any implanted device that is incompatible with MRI.
  • Subjects who have conditions that preclude MRI scanning, e.g., morbid obesity, claustrophobia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cortically Blind Subjects

    Subjects must exhibit unilateral stroke or stroke-like damage to primary visual cortex or its immediate afferent white matter sustained within the specified age range of 21 - 80 years.

    Diagnostic Test: MRI

  • Control Subjects

    Subjects with no history of neurological disorders and normal cognitive abilities.

    Diagnostic Test: MRI

Interventions

  • Diagnostic testMRI

    Functional MRI scan

06

What researchers measure

Primary outcomes

  1. Identify visual areas of damage

    Use fMRI scans to identify areas of damage

    Time frame: Baseline, Visit 2, Optional visits 3-7

  2. Characterize visual response prior to visual training

    Visual responses of different brain areas spared by the patients stroke will be analyzed using a population receptive field (pRF) method.

    Time frame: Baseline, Visit 2, Optional visits 3-7

  3. Characterize how visual response properties in residual visual areas change following a period of visual training

    Characterize how visual response properties in residual visual areas change following a period of visual training. Visual responses of different brain areas will be analyzed using a population receptive field (pRF) method.

    Time frame: Baseline, Visit 2, Optional visits 3-7

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2029, 45 months after the start.

Of 394 non-industry observational studies under Ischemic Stroke, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 45 months is below that.

Counting every sponsor, half of 436 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 21, 2025
StartActual
Oct 17, 2025
Primary completionEst.
Aug 1, 2029
CompletionEst.
Aug 1, 2029
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07134777
Responsible party
Krystel Huxlin (Professor of Ophthalmology, University of Rochester) — Principal investigator
First posted
Aug 21, 2025
Start date
Oct 17, 2025
Primary completion
Aug 1, 2029 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Aug 26, 2026

Study contacts

Evan Burr, BA
Contact
evan_burr@urmc.rochester.edu
585-275-5234

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion